Medinet (2370) · RiskMaterialised
Delay in New Contract Cell-Processing Projects
First written in FY2017-Q3. 3 of 3 entries say "Materialised", first in FY2017-Q3. Latest entry: 2026-10-16.
3entries
10years
1from disclosures
How it moved
Same theme, other companies
Earnings volatility due to failed commissioned projects and delayed negotiationsA theme 15 companies write about · 14 as a headwind · 1 as a tailwind
Medinet moved to the "Worse" side of this theme in 2017, 3 years before the typical company in this theme (2020).
The whole theme swung hardest in 2026: 5 of 7 companies on the "Worse" side.
4 other companies' latest entry also says "Materialised".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 15 companies compared. The sentences above are computed from all 15.Full recordFilings, disclosures and news, newest first
- 2026-10-16MaterialisedRevision of earnings forecasts
「2026 年 9 月期中に製造開始を予定していた複数の受託案件の開始時期が 2027 年 9 月期になった」
CDMO事業で予定されていた複数の受託案件について、製造開始時期のずれ込みが発生した。 - FY2017MaterialisedAnnual report
「Due in part to delays in the start of treatment at existing major medical institutions, which reduced revenue from the manufacture of specified cell-processed products, and delays in scheduled new contract projects for specified cell processing」
Delays in treatment starts at existing major medical institutions and delays in new contract projects were cited as factors behind the full-year decline in cell-processing business revenue. - FY2017-Q3MaterialisedAnnual report
「This was partly due to delays in scheduled new contract cell-processing projects.」
The scheduled start of new contract cell-processing projects was delayed, contributing to lower revenue for the nine-month period.